Feature | August 28, 2012| Nicole Fornell, Pharm D

Use of Platelet Function Testing — Does it really aid patient management?

There is already clinical data to support use of prasugrel, ticagrelor over clopidogrel

Verifynow platelet testing clopidogrel nonresponders

A major issue with clopidogrel is that one-third of patients are nonresponders because they lack the enzymes to metabolize it. While nonresponders can be identified with testing, this adds cost. So with the introduction of the newer antiplatelet agents, which are metabolized differently, some hospitals and physicians are opting for ticagrelor or prasugrel. However, with generic versions of clopidogrel now available at a much lower cost than the newer agents, the question remains if patients should be tested  first to see if they will respond to Plavix.

Patients with 2C19 that is less active due to loss of gene copies are poor metabolizers of clopidogrel, opening patients to the possibility of a higher rate of mayocardial infacrtion (MI). There are assays for platelet function response (VerifyNow) and genetic tests to measure patient response, which could help determine if generic clopdogrel or more expensive agents should be used.

However, Malcolm R. Bell, MBBS, FRACP, FACC, Mayo Clinic, Rochester, Minn., said platelet function tests have only a modest predictive value. He said these tests do not have optimal methods defined and timing is undefined.

Most cardiologists do not use routine platelet testing because the patient is at high risk for poor clinical outcomes. This is because testing only counts for less than 20 percent of hypo responders due to variations in CYP2C19 enzymes. Bell and other experts presenting on antiplatelet response at the American College of Cardiology (ACC) 2012 said there is not enough information to base practice on the results of these tests. Part of the nonresponse issue is due to poor compliance by the patient. Guidelines state a IIb level of evidence to test for a high risk of poor clinical outcomes or to switch agents, but not for routine testing of platelet aggregation.

In an ACC 2012 cardiac pharmacology panel discussion, there was discussion of making platelet response testing a prior authorization requirement before newer, more expensive agents would be covered. But, speakers emphasized there is no data to say that a patient who has sticking platelets on clopidogrel will respond better with another agent. For now, it is not known what to do with this information. 

There is already clinical data to support use of prasugrel and ticagrelor over clopidogrel without testing. Therefore, platelet testing may be a moot point due to the increased cost.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init